# Nuclide record paper-netter-2-lancet-2024 (paper). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/key-papers/paper-netter-2-lancet-2024/>
  a schema:ScholarlyArticle ;
  nuclide:kind "paper" ;
  schema:identifier "paper-netter-2-lancet-2024" ;
  schema:name "NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours"@en ;
  schema:description "Using the radioactive drug lutetium dotatate as the first treatment for faster-growing neuroendocrine tumours, rather than saving it for later, nearly tripled the time without progression compared with high-dose octreotide."@en ;
  schema:url <https://nuclide.cc/key-papers/paper-netter-2-lancet-2024/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=NETTER-2+lutetium+dotatate+first-line+Singh+Lancet>, <https://clinicaltrials.gov/study/NCT03972488> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(24)00701-3> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Singh S, Halperin D, Myrehaug S, et al." ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/neuroendocrine/> ;
  nuclide:technologies <https://nuclide.cc/technologies/radioligand-therapy/>, <https://nuclide.cc/technologies/pet-ct/> ;
  nuclide:targets <https://nuclide.cc/targets/sstr2/> ;
  nuclide:drugs <https://nuclide.cc/drugs/lutathera/> ;
  nuclide:companies <https://nuclide.cc/companies/novartis/> ;
  nuclide:terms <https://nuclide.cc/terms/theranostics/>, <https://nuclide.cc/terms/dosimetry/> ;
  nuclide:journals <https://nuclide.cc/journals/lancet/> .